SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as community members highlight bullish price action and speculate about future growth potential. Conversations mention the potential for significant gains and the coin's strong community support. Some users are drawing comparisons to other meme coins on Solana, suggesting a broader interest in the sector.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members highlight its long-term development on the Solana blockchain and its listing on the Jupiter Strict List. The community is actively using the project's namesake punchline and comparing it to other popular meme coins like $DOGE.X and $SHIB.X, suggesting it could be the next big meme coin.

TOSHI

TOSHI.X is trending as the community rallies around the meme coin, anticipating significant gains and a potential Binance listing soon. Bullish sentiment is fueled by recent listings, the coin's association with Coinbase, and its status as the 'face of base'. Traders are closely watching for a breakout, with some suggesting a coordinated buy to propel the price higher.

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is trending as social media buzz points to strong chart momentum and a potential breakout. The crypto community is signaling a 'buy now' opportunity, anticipating a rapid price increase. Conversations evoke a sense of urgency, suggesting a 'rocket' is about to launch.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates upcoming revenue figures and discusses treasury mechanics.  Enthusiasm is building around its real-world asset (RWA) adoption and potential for significant growth. Some users are also discussing potential integrations with other tokens.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

$GASS.X is trending as community members highlight its potential, drawing comparisons to $PEPE.X due to its connection with creator Matt Furie, and some are pointing to a recent listing. Community members are actively discussing holding for long-term gains, emphasizing accumulation during dips, and expressing excitement about the project's future.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to the formation of its board and after-hours trading activity. However, some investors are concerned about a dilutive deal involving warrants without a lock-up period. The community is actively discussing the potential impact of these factors on the stock's price.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB.X is gaining attention, with community members highlighting its potential for a squeeze and comparing it favorably to other cryptocurrencies. The upcoming halving event and its association with $ICP.X are key points of discussion, with some suggesting it could be the next $BTC.X. Community sentiment is very bullish.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Oncology is trending due to analyst upgrades and upcoming presentations at the ASCO and other medical conferences, highlighting data related to their cancer treatment pipeline. Community members are actively discussing the company's valuation, pipeline potential, and recent insider trading activity. A recent analysis comparing CGEM to a competitor, BDTX, is also circulating.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending with community members expressing bullish sentiment and urging others to buy in before a potential surge. Conversations highlight the token's strong community and potential for significant gains, with some drawing comparisons to other successful meme coins. The broader discussion includes the potential for 'short squeeze' and the presence of 'big names' within the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of CytomX Therapeutics hit their highest levels in nearly two months on Monday after the company&nbsp;posted better-than-expected first-quarter earnings and revealed promising early trial results for its lead oncology candidate.CytomX posted quarterly earnings per share of $0.27, which surpassed analyst estimates of $0.13.&nbsp;Its revenue climbed to $50.92 million, also beating analyst estimates of $35.42 million.CytomX shares surged by 129.4% on Monday, reaching $2.13.The company revealed early Phase 1 trial results showing positive outcomes for CX-2051, an EpCAM-directed Probody antibody-drug conjugate targeting late-line colorectal cancer (CRC).The CTMX-2051-101 Phase 1 study provided these results after beginning the trial in April 2024.&nbsp;The clinical research on April 7 included 25 patients with metastatic CRC who received CX-2051 treatment through seven different dose levels during three-week intervals.Among the 18 patients receiving therapeutic doses of the CX-2051 treatment, 28% reached confirmed partial response according to RECIST v1.1 standards, which surpasses the standard response rates of low to mid-single digits associated with third-line or later colorectal cancer treatments.&nbsp;Patients on CX-2051 received 10 mg/kg, where three out of seven achieved confirmed partial responses.&nbsp;The Disease Control Rate (DCR) reached 94% across these doses while the median progression-free survival stood at 5.8 months.&nbsp;Ten patients stayed on study treatment at the point of data cutoff out of 18 participants.CEO Sean McCarthy, D.Phil., expressed his optimism about the results while confirming that CX-2051 continues to be the company's number one strategic focus.&nbsp;McCarthy said that the findings establish EpCAM as a valuable target in cancer treatment and enable CX-2051 to advance into CRC applications and various other EpCAM-expressing cancer types.The current dose expansion phase will lead CytomX to start a Phase 2 study in early 2026.Additionally, CytomX priced its 76.9 million share secondary offering at $1.30 per share.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,567% increase in 24-hour message volume.One user expressed confidence that the stock could reach $3.50 the following day.&nbsp;<stembedurl>https://stocktwits.com/LittleWhiteBall/message/614390932</stembedurl>Another noted the rarity of a stock rising after a company issues a secondary offering at a significantly lower price.<stembedurl>https://stocktwits.com/engrman1/message/614387241</stembedurl>The stock has risen 100.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug

The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.

Equity

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection PR Newswire VANCOUVER, BC, May...

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed...

What's Going On With CytomX Stock?

CytomX Therapeutics shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8, after the close...

HC Wainwright Comments on CytomX Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX  Free Report)  Research analysts at HC Wainwright issued their FY2025 EPS estimates for CytomX Therapeutics in a report released on Monday...

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...

CytomX Therapeutics announces milestone achievement in PROBODY TCB

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytomX Therapeutics Announces Milestone Achievement in PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$2.90
Prev Close	$2.84
Open	$3.02
Dividend Yield	0.00%
50-Day Moving Average	$2.17
Beta	1.27
Avg. Volume	3.79M
PE Ratio	5.07

52-Week High	$3.26
52-Week Low	$0.40
Market Capitalization	$478.25M
EPS (Annual)	$0.3761
Price to Book	3.99
Revenue Per Employee	$1.14M
Enterprise Value/EBITDA	N/A

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTMX News

CTMX CytomX Therapeutics Inc